The Goldman Sachs Group Begins Coverage on DexCom (NASDAQ:DXCM)
The Goldman Sachs Group began coverage on shares of DexCom (NASDAQ:DXCM – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $104.00 price objective on the medical device company’s stock. Other equities analysts have also issued reports about the stock. Canaccord Genuity […]
The Goldman Sachs Group began coverage on shares of DexCom (NASDAQ:DXCM – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $104.00 price objective on the medical device company’s stock. Other equities analysts have also issued reports about the stock. Canaccord Genuity […]
